528 related articles for article (PubMed ID: 10747021)
1. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
[TBL] [Abstract][Full Text] [Related]
2. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
4. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
Hetian L; Ping A; Shumei S; Xiaoying L; Luowen H; Jian W; Lin M; Meisheng L; Junshan Y; Chengchao S
J Biol Chem; 2002 Nov; 277(45):43137-42. PubMed ID: 12183450
[TBL] [Abstract][Full Text] [Related]
5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.
Zhu Z; Lu D; Kotanides H; Santiago A; Jimenez X; Simcox T; Hicklin DJ; Bohlen P; Witte L
Cancer Lett; 1999 Mar; 136(2):203-13. PubMed ID: 10355750
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165.
Soker S; Gollamudi-Payne S; Fidder H; Charmahelli H; Klagsbrun M
J Biol Chem; 1997 Dec; 272(50):31582-8. PubMed ID: 9395496
[TBL] [Abstract][Full Text] [Related]
9. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
[TBL] [Abstract][Full Text] [Related]
10. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.
Waltenberger J; Mayr U; Frank H; Hombach V
J Mol Cell Cardiol; 1996 Jul; 28(7):1523-9. PubMed ID: 8841939
[TBL] [Abstract][Full Text] [Related]
11. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.
Dougher AM; Wasserstrom H; Torley L; Shridaran L; Westdock P; Hileman RE; Fromm JR; Anderberg R; Lyman S; Linhardt RJ; Kaplan J; Terman BI
Growth Factors; 1997; 14(4):257-68. PubMed ID: 9386990
[TBL] [Abstract][Full Text] [Related]
12. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
13. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
[TBL] [Abstract][Full Text] [Related]
14. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
15. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.
Keyt BA; Nguyen HV; Berleau LT; Duarte CM; Park J; Chen H; Ferrara N
J Biol Chem; 1996 Mar; 271(10):5638-46. PubMed ID: 8621427
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
18. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes.
Hamma-Kourbali Y; Vassy R; Starzec A; Le Meuth-Metzinger V; Oudar O; Bagheri-Yarmand R; Perret G; Crépin M
J Biol Chem; 2001 Oct; 276(43):39748-54. PubMed ID: 11514538
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
